Anal cancer in Sweden 2015–2019. Implementation of guidelines, structural changes, national registry and early results. (4th May 2022)

• Record Type: Journal Article
• Authors: Johnsson, Anders; Norman, David; Angenete, Eva; Cavalli-Björkman, Nina; Lagerbäck, Cecilia; Leon, Otilia; Lindh, Birgitta; Lydrup, Marie-Louise; Nilsson, Martin P.; Perman, Mats; Radu, Calin; Zackrisson, Björn
• Is Part Of: Acta oncologica. Volume 61:Number 5(2022)
• Page Start: 575
• Page End: 582
• Publication Date: 2022-05-04
• Subjects: Anal cancer -- guidelines -- chemoradiotherapy; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2022.2048069
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Background: Squamous cell cancer of the anus is an uncommon malignancy, usually caused by human papilloma virus (HPV). Chemoradiotherapy (CRT) is the recommended treatment in localized disease with cure rates of 60–80%. Local failures should be considered for salvage surgery. With the purpose of improving and equalizing the anal cancer care in Sweden, a number of actions were taken between 2015 and 2017. The aim of this study was to describe the implementation of guidelines and organizational changes and to present early results from the first 5 years of the Swedish anal cancer registry (SACR). Methods: The following were implemented: (1) the first national care program with treatment guidelines, (2) standardized care process, (3) centralization of CRT to four centers and salvage surgery to two centers, (4) weekly national multidisciplinary team meetings where all new cases are discussed, (5) the Swedish anal cancer registry (SACR) was started in 2015. Results: The SACR included 912 patients with a diagnosis of anal cancer from 2015 to 2019, reaching a national coverage of 95%. We could show that guidelines issued in 2017 regarding staging procedures and radiotherapy dose modifications were rapidly implemented. At baseline 52% of patients had lymph node metastases and 9% had distant metastases. Out of all patients in the SACR 89% were treated with curative intent, most of them with CRT, after which 92% achieved a local complete remission and the estimated overall 3-year survival was 85%. Conclusions: This is the first report from the SACR, demonstrating rapid nation-wide implementation of guidelines and apparently good treatment outcome in patients with anal cancer in Sweden. The SACR will hopefully be a valuable source for future research.